Clinical trial
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C…
NCT00136318 · Charite University, Berlin, Germany, Other · Completed
Key facts
| NCT number | NCT00136318 |
|---|---|
| Title | Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients |
| Official title | Efficacy and Tolerability of Escitalopram for the Prevention of Pegylated Interferon Alfa Associated Depression in Patients With Chronic Hepatitis C Infection: a Randomized Controlled Trial. |
| Acronym | CIPPAD |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depression |
| Intervention type | Drug |
| Interventions | Escitalopram, Placebo, Peginterferon alfa-2a, Ribavirin |
| Enrollment | 208 |
| Start date | Jan 1, 2004 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Aug 29, 2005 |
| Last update posted | Mar 21, 2013 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: